Download Free Medical Cancer Survivorship - Prostate Cancer Risks and Treatments PowerPoint Presentation

Cancer Survivorship - Prostate Cancer Risks and Treatments PowerPoint Presentation

DOWNLOAD MEDICAL POWERPOINT PRESENTATION

About This Presentation

Description : This medical presentation on cancer titled "Cancer Survivorship - Prostate Cancer Risks and Treatments" is a very edifying, interactive and self-directed learning module expected to prepare a foundation of knowledge covering the epidemiology and late effects of cancer survival. This presentation covers covers topics like epidemiology of cancer survival, its late effects, psychosocial concerns, secondary prevention, and strategies for behavior change.

Tags : Cancer, Survivorship, Prostate Cancer, Risks, Treatments, epidemiology, late effects, psychosocial concerns, secondary prevention, strategies for behavior change

Published on : May 03, 2021 | Views : 1981 | Downloads : 2

Shareable Url :

Embed Code :

Comment

Transcript

Slide 1-

Cancer Survivorship Prostate Cancer Risks and Treatments © 2005 University of California Regents Cancer Survivorship Grant Start Case Photo collection is courtesy of PEIR - University of Alabama at Birmingham Department of Pathology via the HEAL (Health Education Asset Library) database
Slide 2-

Goal of this Module This is an interactive and self-directed learning module intended to build a foundation of knowledge around the epidemiology and late effects of cancer survival. This is one of several educational modules you will complete during your core clinical clerkships. Themes emphasized in this, and other modules, are: Epidemiology of survival Late effects Psychosocial concerns Secondary prevention Strategies for behavior change Meet your patient
Slide 3-

Paul R. State III is a 55-year old African-American male who presents to a family practice clinic because his wife insists he have a prostate evaluation. He is in good health and has no active medical issues or symptoms. He has not seen a doctor in over 5 years, but his 51-year old brother was recently diagnosed with prostate cancer and Mr. State’s wife insisted that he be evaluated for prostate cancer, as well. He had a prostate-specific antigen (PSA) test done a few weeks ago, and Mrs. State says you should have the results in the computer. He reports no obstructive symptoms of hesitancy, incomplete emptying, double voiding, or dribbling. He has no irritative symptoms of urgency, frequency, or nocturia. Case continued
Slide 4-

Case continued Family history is significant only for his brother who was recently diagnosed with prostate cancer. He has smoked 2 packs of cigarettes a day since he was 20 years old, drinks 1-2 beers per day, and denies using drugs. He works as a manager at a local car garage. He eats fast food daily because he can’t resist double doubles from In-N-Out next to his shop. His wife leaves the room for the physical exam. As soon as she leaves, he says “I’m not really at risk for prostate cancer, right doc? I just want my wife to get off my back.” Go to Question #1
Slide 5-

Question #1: Which of Mr. State’s risk factors poses the largest relative risk for prostate cancer? Ethnicity Age Family History Diet Environmental Exposure
Slide 6-

Question #1: Incorrect Answer Ethnicity: African-Americans are at higher risk for prostate cancer than matched Caucasians. On average, they present with more advanced disease at initial diagnosis. The potential increased mortality for African-Americans compared to Caucasians is controversial. Prostate cancer screening should begin at 40 years of age for African-Americans. Ethnicity does not pose the largest relative risk in this patient. Return to Question #1 Ethnicity article (Kang, BJU 2004)
Slide 7-

Question #1: Correct Answer Age: The incidence of prostate cancer increases with age. Clinically significant prostate cancer develops in 0.01% of men<40 years old, 1% of men 40-59 years old, and 13% of men over the age of 60. Continue case Age article (Thompson, NEJM 2004)
Slide 8-

Question #1: Incorrect Answer C. Family History: The age at which the disease was diagnosed in a first-degree family member is vital to determining the relative risk for Mr. State. The relative risk for prostate cancer is 4-7x if the age of onset was 50 years old, 3-5x if the age of onset was 60 years old, and 2-4x if the age of onset was 70 years old. Prostate cancer screening should begin at 40 years of age for patients with a family history of prostate cancer. Return to Question #1 Family history article (Thompson, NEJM 2004)
Slide 9-

Question #1: Incorrect Answer D. Diet: Although high fat intake doubles Mr. States risk of prostate cancer, diet does not pose the largest relative risk. Return to Question #1 Diet article (Mazhar: BJU 2004)
Slide 10-

Question #1: Incorrect Answer E. Environmental exposure: His risk of prostate cancer increases with exposure to alkaline batteries, welding chemicals, and, possibly, tobacco (all contain cadmium, which is carcinogenic in the prostate.) However, these exposures do not pose the largest relative risk. Return to Question #1 Environmental exposure article (Deutsch: Lancet Oncol 2004)
Slide 11-

Case Continued On physical exam, Mr. State is obese and in no apparent distress. HEENT, cardiovascular, pulmonary, and abdominal exams are within normal limits. Continue case
Slide 12-

Case Continued On rectal exam, sphincter tone is normal. The prostate margins are distinct and it appears to be normal in size, but a firm, 0.5 cm x 0.5 cm nodule is palpated along the right lateral sulcus. After the exam, you remember to check Mr. State’s labs on the computer. CBC and Chem-7 are within normal limits. PSA is 4.8. Go to Question #2
Slide 13-

Question #2: Which of the following factors will allow you to decide definitively whether Mr. State has prostate cancer? PSA velocity Age-adjusted PSA PSA density Ratio of free PSA to bound PSA None of the above
Slide 14-

Question #2: Incorrect Answer A. PSA velocity: A change in PSA (PSA velocity) of >1.5 ng/mL over 2 years may be associated with prostate cancer. However, the same laboratory should be used, and even then PSA velocity has a low sensitivity and specificity for prostate cancer. Return to Question #2 PSA velocity article (D’ Amico: NEJM 2004)
Slide 15-

Question #2: Incorrect Answer B. Age-adjusted PSA: Adjusting PSA for age increases the sensitivity for younger men and specificity for older men. The normal range, in ng/mL, is 0-2.5 for 40-49 year olds, 0-3.5 for 50-59 year olds, 0-4.5 for 60-69 year olds, and 0-6.5 for 70-79 year olds. However, PSA is useful only as a screening tool, not for definitive diagnosis. Return to Question #2 Age-adjusted PSA article (Chu, Cancer 2002)
Slide 16-

Question #2: Incorrect Answer C. PSA density: The PSA density adjusts for benign prostatic hyperplasia (BPH), since 1 gram of BPH tissue elevates PSA by approximately 0.12 ng/mL. While a PSA density >0.15 is more likely to warrant a biopsy, it only raises the positive predictive value to 30-40%. Return to Question #2 PSA density (D’Amico: NEJM 2004)
Slide 17-

Question #2: Incorrect Answer D. Ratio of free PSA to bound PSA: Normally, approximately 90% of PSA is bound to alpha-1-antichymotrypsin. Free PSA levels below 21% tend to correlate with prostate cancer, while levels above 21% are often seen in older men whose disease is slowly progressing. These ratios, however, must be correlated with other studies. Return to Question #2 Ratio of free PSA to bound PSA article (Uemura: Int J Urol 2004)
Slide 18-

Question #2: Correct Answer E. None of the above: PSA>4ng/mL has a positive predictive value of 20-30% for carcinoma of the prostate. While each of the above adjustments is useful in improving the sensitivity and specificity of the test to some extent, PSA should still be used to guide a further work-up and should be considered in the context of the patient’s other personal risk factors, history, physical exam, and other findings. PSA may be elevated secondary to BPH, urethral instrumentation, infection, prostatic infarction, or prostatic massage. The only way to definitively diagnose prostate cancer is with biopsy. Continue case
Slide 19-

Case Continued You tell Mr. State that you would like to perform a trans-rectal ultrasound (TRUS)-guided biopsy. He argues that it is an uncomfortable procedure and says he doesn’t see the point, but Mrs. State chides him that “the doctor knows best”. He agrees to the procedure. Before performing the TRUS, you try to predict where a potential cancer might be found. Go to Question #3
Slide 20-

TRUS-Guided Bx Back to case The most common adverse event of prostate biopsy is rectal bleeding, which occurs in up to 50% of patients but rarely needs to be packed for tamponade. The most common minor complication is prostatitis, which occurs in approximately 2.5% of patients. Infectious complications requiring hospitalization are seen in <1% of patients who are properly medicated with antibiotics before biopsy.
Slide 21-

Question #3: In which zone of the prostate will carcinoma most likely arise? Transition zone Peripheral zone Central zone Anterior fibromuscular area
Slide 22-

Question #3: Incorrect Answer Transition zone: 10-20% of prostatic carcinoma arises in the transition zone. Benign prostatic hyperplasia almost always occurs in the transition zone. Return to Question #3
Slide 23-

Question #3: Correct Answer B. Peripheral zone: 65-70% of prostatic carcinoma arises in the peripheral zone. The peripheral zone can be palpated on digital rectal exam (DRE), making DRE a useful screening tool for prostate cancer. Continue case
Slide 24-

Question #3: Incorrect Answer C. Central zone: About 5% of prostate cancer arises in the central zone. Return to Question #3
Slide 25-

Question #3: Incorrect Answer D. Anterior fibromuscular area: Prostatic cancer rarely arises in the anterior fibromuscular area. Return to Question #3
Slide 26-

Case Continued After pre-medication with broad-spectrum antibiotics, TRUS is performed and shows a hypoechoic pattern in the peripheral zone and the left base. Core biopsies of the hypoechoic area are taken and random sampling is done by dodecad biopsies. You go to the pathology lab to review the findings so you can sound smart if your attending questions you. To your dismay, the pathologist asks you a series of questions before reviewing the slides with you. Go to Question #4
Slide 27-

Question #4: If Mr. State has cancer of the prostate, which is the most likely histology? Small cell carcinoma Sarcoma Adenocarcinoma Transitional cell carcinoma
Slide 28-

Question #4: Incorrect Answer Small cell carcinoma: Small cell carcinomas account for less than 1% of prostate cancer. Return to Question #4
Slide 29-

Question #4: Incorrect Answer B. Sarcoma: Sarcomas account for less than 1% of prostate cancer. Return to Question #4
Slide 30-

Question #4: Correct Answer C. Adenocarcinoma: Adenocarcinomas account for over 95% of prostate cancers. The distinguishing histologic characteristic of prostate cancer is the absence of basal cells, which can be seen with high-molecular-weight keratin staining (which stains basal cells). Absence of staining is consistent with carcinoma of the prostate. Continue case
Slide 31-

Question #4: Incorrect Answer D. Transitional cell carcinoma: Transitional cell carcinomas account for approximately 4% of prostate cancer. They do account for over 90% of bladder cancer. Return to Question #4
Slide 32-

Case Continued Upon viewing the slides with the pathologist, you note a basophilic cytoplasm with enlarged, hyperchromatic nuclei with enlarged nucleoli. You ask the pathologist if she has stained the cells with high-molecular-weight keratin and, impressed by your knowledge, she says she has and points out the absence of staining where the basal cell layer is normally found. The pathologist asks how prostatic cancer is graded. After you correctly identify the Gleason grading system, she asks about the significance of different Gleason scores. Go to Question #5
Slide 33-

Gleason Score The Gleason grading system is based on the glandular architecture of prostatic samples under low power: ▪ Grade 1 or 2: samples are closely packed, have little stroma, and are small and uniform. ▪ Grade 3: samples have variable-sized glands between normal stroma. ▪ Grade 4: samples have incomplete gland formation. ▪ Grade 5: samples have no gland formation or lumen appearance, or they may (rarely) be comedocarcinoma. The Gleason score is the sum of the most commonly found pattern and the second most commonly found pattern. The primary Gleason grade is more important than the second one, so Gleason 6 (4+2) is more poorly differentiated than Gleason 6 (3+3). Return to Question #5
Slide 34-

Question #5: What Gleason score would suggest that Mr. State’s cancer is poorly differentiated? Gleason 2 (1+1) Gleason 4 (2+2) Gleason 6 (3+3) Gleason 10 (5+5)
Slide 35-

Question #5: Incorrect Answer Gleason 2 (1+1): Gleason 2 (1+1) is considered very well-differentiated. Return to Question #5 Normal Gleason 1
Slide 36-

Question #5: Incorrect Answer B. Gleason 4 (2+2): Gleason 4 (2+2) is considered well-differentiated. Return to Question #5 Normal Gleason 2
Slide 37-

Question #5: Incorrect Answer C. Gleason 6 (3+3): Gleason 5-6 is considered moderately differentiated. The primary Gleason grade is more important than the second one, so Gleason 6 (4+2) is more poorly differentiated than Gleason 6 (3+3). Return to Question #5 Normal Gleason 3
Slide 38-

Question #5: Correct Answer D. Gleason 10 (5+5): Gleason 8-10 is considered poorly differentiated. Continue Case Normal Gleason 5
Slide 39-

Case Continued Mr. State’s Gleason score is 7 (4+3). Continue Case Normal Gleason 4 Gleason 3
Slide 40-

Case Continued Mr. State now inquires about the clinical stage of his prostate cancer. Go to Question #6
Slide 41-

Question #6: Evidence supports the usefulness of which of the following possible staging modalities for localized prostate cancer? Pelvic CT PSA Digital Rectal Exam (DRE) Trans-rectal ultrasound Radionuclide bone scan
Slide 42-

Question #6: Incorrect Answer Pelvic CT: Pelvic CT is rarely used to assess whether pelvic lymph nodes are enlarged, a finding that would suggest possible nodal metastasis. Because lymph node metastasis is exceedingly rare with Gleason score ≤ 7 and PSA < 10, pelvic CT is not routinely done with these values unless clinically indicated. Return to Question #6
Slide 43-

Question #6: Incorrect Answer B. PSA: Serum PSA correlates very roughly with tumor extent. Return to Question #6
Slide 44-

Question #6: Correct Answer C. DRE: Since prostatic carcinoma is staged by the TNM system, DRE is used to assess the primary tumor (T stage). Because lymph node or other metastasis is exceedingly rare with Gleason score ≤ 7 and PSA < 10, no nodal involvement (N0) or metastasis (M0) is assumed for clinical staging purposes. Go to Question #7
Slide 45-

Question #6: Incorrect Answer D. Trans-rectal ultrasound (TRUS): TRUS is typically used to direct biopsy, not for staging. Return to Question #6
Slide 46-

Question #6: Incorrect Answer E. Radionuclide bone scan: Bony metastases are rare with a PSA < 20 ng/mL. Although radionuclide bone scanning is very sensitive to detect bony metastasis, it is not routinely done with a PSA < 10 if the Gleason score is ≤ 7. Return to Question #6
Slide 47-

Question #7: What is the CLINICAL STAGE of Mr. State’s carcinoma? T1N0M0 T2N0M0 T3N1M0 T4N1M0 T4N1M1 Click here to see the stages
Slide 48-

Go to N Stage Most common clinical stage since screening with PSA was instituted.
Slide 49-

Go to M Stage
Slide 50-

Return to Question #7
Slide 51-

Question #7: Incorrect Answer T1N0M0: T1 tumors have a normal digital rectal exam (DRE). These are the most common tumors diagnosed and are detected by biopsy following an abnormal PSA. Since routine PSA screening was instituted, this has been by far the most common clinical stage of prostate cancer. Return to Question #7
Slide 52-

Question #7: Correct Answer B. T2N0M0: T2 tumors are either palpable by DRE or visible by trans-rectal ultrasound (TRUS), but are confined to the prostate. T2a tumors involve less than half of one lobe, T2b involve more than half of one lobe but not both lobes, and T2c tumors are bilateral. With Mr. State’s PSA of 4.8, no nodal metastasis is assumed for the clinical staging, as lymph node metastases are exceedingly rare with Gleason <7 and PSA <10 Continue Case
Slide 53-

Question #7: Incorrect Answer C. T3N1M0: T3 tumors have extracapsular extension. T3b involves the seminal vesicles. N1 indicates nodal involvement. Return to Question #7
Slide 54-

Question #7: Incorrect Answer D. T4N1M0: T4 tumors extend into the bladder neck, sphincter, levator muscles, pelvic sidewall, or rectum (involvement of the rectum is rare because of the strength of Denonvillier’s fascia separating the prostate from the rectum). N1 indicates nodal involvement. M1 indicates metastases: M1a to nonregional lymph, M1b to bone (typically osteoblastic lesions), and M1c to other sites. Return to Question #7
Slide 55-

Question #7: Incorrect Answer E. T4N1M1: T4 tumors extend into the bladder neck, sphincter, rectum, levator muscles, or pelvic sidewall. N1 indicates nodal involvement. Return to Question #7
Slide 56-

Case Continued Mr. State inquires about his different treatment options. You explain that the major categorical options include watchful waiting, radiation therapy, and radical prostatectomy. You recommend the National Cancer Institute (NCI) website discussion on treatment options. http://www.nci.nih.gov/cancertopics/understanding-prostate-cancer-treatment/page5 Continue Case
Slide 57-

Case Continued At this time, he has normal erections sufficient for penetration and no urinary incontinence. Despite his high-fat diet, his lipid panel is within normal limits and he has no other cardiovascular risk factors other than smoking and obesity (BMI 32). On review of systems, he appears to be in good health. Continue Case
Slide 58-

Case Continued Mr. State is not enthusiastic about surgery or radiation and says “Doc, if I just wait and don’t do anything else, won’t I die of something else before the prostate cancer gets me?” Go to Question #8
Slide 59-

Question #8: What is the likelihood that Mr. State will die of prostate cancer within 10 years if he chooses watchful waiting? 1% 15% 50% 95%
Slide 60-

Question #8: Incorrect Answer 1%: Very few prostate cancers are indolent enough to have a 10 year disease-specific mortality of ≤ 1% Return to Question #8
Slide 61-

Question #8: Correct Answer 15%: Results of most watchful waiting studies suggest a 10-year disease-specific mortality of approximately 10-15%, although there is a wide variability based on patient population (4-45%). Watchful waiting may be an appropriate option for an older patient with many co-morbidities, because non-prostate cancer-related mortality is high and the patient is likely to die of another disease before he dies of prostate cancer. Watchful waiting article #1 (Johansson: JAMA 2004) Watchful waiting article #2 (Bil-Axelson: NEJM 2005) Continue case
Slide 62-

Question #8: Incorrect Answer C. 50%: While some prostate cancers are aggressive enough to result in disease-specific death within 10 years, most are less aggressive. Return to Question #8
Slide 63-

Question #8: Incorrect Answer D. 95%: Very few prostate cancers are aggressive enough to have a 10 year disease-specific mortality of ≥ 95% Return to Question #8
Slide 64-

Case Continued After hearing your discussion of the watchful waiting option, Mr. State wants to know more about radiation therapy. A family friend who had prostate cancer 10 years ago and was treated with external beam therapy had terrible side-effects and discontinued treatment before completing the entire course. His cancer recurred within 5 years and he passed away. Mr. State is concerned about the side-effects of radiation therapy. Go to Question #9 Radiation therapy article (Nilsson, Acta Oncol, 2004)
Slide 65-

Question #9: Which of the following are potential complications of radiation treatment? Frequency Fatigue Impotence Bowel bother All of the above
Slide 66-

Question #9: Incorrect Answer Frequency: Most patients experience urinary frequency and dysuria. Over 90% of these cases, however, resolve within one year. Back to Question #9
Slide 67-

Question #9: Incorrect Answer B. Fatigue: The degree of fatigue is variable, but significant in up to 75% of patients during radiation treatment. Within 2-3 months of treatment completion, most patients return to baseline energy levels. Back to Question #9
Slide 68-

Question #9: Incorrect Answer C. Impotence: Impotence has been reported in up to 35-40% of patients. Back to Question #9
Slide 69-

Question #9: Incorrect Answer D. Bowel bother: Mild, self-limited rectal bleeding is present in approximately 10% of patients. Back to Question #9
Slide 70-

Question #9: Correct Answer E. All of the above. Frequency, fatigue, impotence, and bowel bother are all potential side-effects of radiation therapy. Continue Case
Slide 71-

Case Continued Mr. State now inquires about survival rates after radiation therapy. Go to Question # 10
Slide 72-

Question #10: What are overall and disease-specific 10-year survival after radiation therapy? 80% and 90%, respectively 60% and 70%, respectively 40% and 50%, respectively
Slide 73-

Question #10: Correct Answer 80% & 90%: Overall 10-year survival after radiation therapy is approximately 80%. Disease-specific survival is approximately 90%. These results indicate that approximately 20% of patients with prostate cancer treated with radiation therapy die within 10 years, with half (10%) dying of prostate cancer. Continue Case
Slide 74-

Question #10: Incorrect Answer B. 60% & 70%: Both overall and disease-specific 10-year survival are significantly better than 60% and 70%, respectively. Return to Question #10
Slide 75-

Question #10: Incorrect Answer C. 40% & 50%: Both overall and disease-specific 10-year survival are significantly better than 40% and 50%, respectively. . Return to Question #10
Slide 76-

Case Continued Mr. State now wants to know more about radical prostatectomy. You explain that the procedure entails a 2-3 hour operation that generally requires a 2-3 day hospital stay. He will be able to donate autologous units of blood to minimize the likelihood of transfusion reaction if transfusion becomes necessary. He will have a catheter to drain his bladder for the first 7-10 days after surgery. Continue Case
Slide 77-

Case Continued You discuss potential complications of radical prostatectomy, including blood loss, incontinence, and impotence. You explain that reports of post-operative potency after radical prostatectomy vary widely based on surgical techniques, patient population, and method of data collection. If potency does return, it will typically return within 6-12 months post-operatively, with significant variability. Go to Question #11
Slide 78-

Question #11: If he chooses surgery, Mr. State’s post-operative potency will be most strongly influenced by which of the following? Tumor size Pre-operative PSA Age Surgical technique Baseline potency article (Hu, J Urol 2004)
Slide 79-

Question #11: Incorrect Answer Tumor size: Tumor size correlates very roughly with post-operative potency. Extremely large tumors, however, are associated with a higher likelihood of capsular penetration, often precluding nerve-sparing operative techniques. Return to Question #11
Slide 80-

Question #11: Incorrect Answer B. Pre-operative PSA: Pre-operative PSA correlates very roughly with post-operative potency. PSA>10, however, is associated with a higher likelihood of capsular penetration, often precluding nerve-sparing operative techniques. Return to Question #11
Slide 81-

Question #11: Correct Answer C. Age: Patient age is the strongest predictive factor for post-operative potency. Increasing age is inversely proportional to post-operative potency. Reports of potency rates for men under 60 range from 20-80%, for men 60-79 from 10-70%, and for men >80 years of age from 5-70%. Although surgical technique and other factors also influence post-operative potency, age is the most important factor. Go to Question #12
Slide 82-

Question #11: Incorrect Answer D. Surgical technique: Reports of potency rates for men under 60 after bilateral nerve-sparing operations range from 40-80%, but drop to 20-60% after unilateral nerve-sparing operations. The respective rates are 25-75% and 10-50% in men over the age of 60. Surgical technique is not the strongest predictor of post-operative potency. Return to Question #11
Slide 83-

Question #12: If he chooses surgery, what is the likelihood he will be continent of urine within 1 year? 10% 35% 60% 85% Continent article (Hu, J Urol 2004)
Slide 84-

Question #12: Incorrect Answer A. 10%: Most patients are continent of urine within 1 year. Return to Question #12
Slide 85-

Question #12: Incorrect Answer B. 35%: Most patients are continent of urine within 1 year. Return to Question #12
Slide 86-

Question #12: Incorrect Answer C. 60%: >60% of patients are continent of urine within 1 year. Return to Question #12
Slide 87-

Question #12: Correct Answer D. 85%: The rate of complete post-operative urinary incontinence is approximately 3%, but the rate of mild stress urinary incontinence may be as high as 20%. Return to continence is gradual, with 50% of patients continent 3 months post-operatively and approximately 75% continent at 6 months. Although most patients report no significant incontinence after one year, only 60-65% report restoration of baseline continence (i.e. they have minor episodes of incontinence that they do not deem significant). Continue Case
Slide 88-

Case Continued Based on Mr. States clinical exam, PSA and biopsy results you use a Partin table to determine there is a 67% likelihood his prostate cancer is confined to the prostate. Continue Case
Slide 89-

Case Continued Mr. State chooses to undergo radical prostatectomy. His final surgical pathology is Gleason (4+3=7) confined to the prostate. Go to Question #13
Slide 90-

Question #13: In this patient, what is the likelihood of disease-free 10 year survival? 40% 60% 80% 95% Disease-free 10 year survival article (Roehl, J Urol 2004)
Slide 91-

Question #13: Incorrect Answer 40%: Patients with extensive extracapsular extension have 70% 5-year disease-free survival rates and 40% 10-year survival rates. Return to Question #13
Slide 92-

Question #13: Incorrect Answer B. 60%: Because he does not have extracapsular extension, the probability of disease-free 10 year survival is better than 60%. Return to Question #13
Slide 93-

Question #13: Correct Answer C. 80%: Patients with organ-confined prostate cancer have approximately 80% 10-year disease-free survival rates. Continue Case
Slide 94-

Question #13: Incorrect Answer D. 95%: Even if he had extracapsular extension there would be a >5% possibility of disease-specific 10 year mortality. Return to Question #13
Slide 95-

Case Continued Mr. State does well after surgery. His catheter is removed 10 days post-operatively and his wounds are well-healed. You schedule a follow-up appointment for 3 months. Continue Case
Slide 96-

Case Continued Mr. State comes for a 3 month follow-up. He has occasional loss of urine when he plays tennis, but is otherwise fully continent. He has begun having satisfactory erections again. You discuss cancer surveillance. Go to Question #14
Slide 97-

Question #14: What is the best way to test for recurrence of Mr. State’s prostate cancer? Bone scan PSA Chest X-ray Physical exam
Slide 98-

Question #14: Incorrect Answer Bone scan: Unnecessary due to the low likelihood of bone metastasis. Return to Question #14
Slide 99-

Question #14: Correct Answer B. PSA: PSA levels should be undetectable following radical prostatectomy. This test is typically ordered at the 3 month follow-up visit. Rising PSA levels suggest biochemical disease recurrence. Continue case
Slide 100-

Question #14: Incorrect Answer C. Chest X-ray: Unnecessary due to the low likelihood of bone metastasis. Return to Question #14
Slide 101-

Question #14: Incorrect Answer D. Physical exam: Should be performed, but will only identify gross disease, which is highly unlikely in this patient. Return to Question #14
Slide 102-

Case Continued Mr. State’s PSA is undetectable. He returns 9 months later (1 year post-operatively) to recheck his PSA, which is <0.1. He has returned to full continence and is having satisfactory erections. He passes away 10 years later of unrelated cardiovascular disease. End case
Slide 103-

Thank you. You have successfully completed this cancer survivorship case. Start of case This case was developed by Steve Lerman, MD and Jonathan Bergman, MD, Department of Urology This module was designed by Tatum Langford Korin and Sarah Afrand, Instructional Design & Technology Unit Cancer Survivorship Grant Project # © 2005, University of California Regents To leave case hit ‘Esc’ (Escape) on your keyboard -found in the upper left corner Photo collection is courtesy of PEIR - University of Alabama at Birmingham Department of Pathology via the HEAL (Health Education Asset Library) database Please provide feedback by completing an online Evaluation
Slide 104-

Glossary Dodecad Biopsy: During prostate biopsy, 12 or more samples are taken to increase the likelihood of detecting cancer if it is present. Return to case
Slide 105-

Glossary Hypoechoic: A region through which ultrasonography cannot penetrate; this region usually represents a prostatic nodule (red arrows). Return to case Prostate transverse section
Slide 106-

Glossary Autologous: One’s own blood. By donating blood to themselves pre-operatively, patients can decrease the risk of transfusion reaction if they require an intraoperative or postoperative blood transfusion. Donation is done a few months prior to the procedure so the patient’s red blood cell count can re-stabilize. Return to case
Slide 107-

Partin Tables Partin coefficient tables estimate prognosis by determining four probabilities: The probability that the patient has completely organ-confined disease The probability that the patient has “established capsular penetration” The probability that the patient has extension of his prostate cancer into his seminal vesicles The probability that the patient has prostate cancer which has spread into his lymph nodes Return to case Partin Table (word document)
Slide 108-

Gleason Score The Gleason grading system is based on the glandular architecture of prostatic cells under low power. Grade 1 or 2 cells are closely packed, have little stroma, and are small and uniform. Grade 3 cells have variable-sized glands between normal stroma. Grade 4 cells have incomplete gland formation. Grade 5 cells have no gland formation or lumen appearance, or they may (rarely) be comedocarcinoma. The Gleason score is the sum of the most commonly found cell and the second most commonly found cell. The primary Gleason grade is more important than the second one, so Gleason 6 (4+2) is more poorly differentiated than Gleason 6 (3+3). Return to Case
Slide 109-

Clinical versus Pathological Staging Clinical staging of prostate cancer involves estimation of disease extent based on physical examination, laboratory studies, and imaging studies. Pathological staging involves analysis of the removed specimen, as well. The pathologic stage of prostate cancer is as advanced as the clinical stage in 30% of cases, more advanced in 70% of cases, and rarely less advanced. Return to Case
Slide 110-

Clinical versus Pathological Staging Clinical staging of prostate cancer involves estimation of disease extent based on physical examination, laboratory studies, and imaging studies. Pathological staging involves analysis of the removed specimen, as well. The pathologic stage of prostate cancer is as advanced as the clinical stage in 30% of cases, more advanced in 70% of cases, and rarely less advanced. Return to Question #7
Slide 111-

Denonvillier’s fascia Denonvillier’s fascia Back to Previous slide
Slide 112-

Disease-Free Survival Disease-free survival is the length of time a patient lives with no evidence of the disease in question. If a prostate cancer patient were alive 10 years after radical prostatectomy, but with a rising PSA, the patient would be categorized as a cancer survivor, but not a disease-free survivor. Return to Question #13
Slide 113-

Obesity Obesity is currently defined by body mass index (BMI). A BMI of 25-29 kg/m2 is overweight, 30-39 kg/m2 is obese, and >40 kg/m2 is morbidly obese. Return to Text
Slide 114-

Disease-Free Survival Disease-free survival is the length of time a patient lives with no evidence of the disease in question. If a prostate cancer patient were alive 10 years after radical prostatectomy, but with a rising PSA, the patient would be categorized as a cancer survivor, but not a disease-free survivor. Return to Question #10